$9.21
8.35% day before yesterday
Nasdaq, Aug 22, 10:08 pm CET
ISIN
US4831191030
Symbol
KALA

Kala Pharmaceuticals, Inc. Stock price

$9.21
+3.71 67.45% 1M
+2.57 38.70% 6M
+2.27 32.71% YTD
+3.21 53.50% 1Y
-5.28 36.42% 3Y
-440.84 97.95% 5Y
-914.37 99.00% 10Y
-914.37 99.00% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.71 8.35%
ISIN
US4831191030
Symbol
KALA
Industry

Key metrics

Basic
Market capitalization
$64.7m
Enterprise Value
$53.1m
Net debt
positive
Cash
$42.2m
Shares outstanding
6.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
11.3
Financial Health
Equity Ratio
22.2%
Return on Equity
-316.3%
ROCE
-157.2%
ROIC
-
Debt/Equity
5.4
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-39.5m | -
EBIT
$-39.7m | $-46.7m
Net Income
$-35.7m | $-37.2m
Free Cash Flow
$-27.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
0.6% | -
EBIT
0.6% | -14.0%
Net Income
10.3% | 4.6%
Free Cash Flow
8.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-5.6
FCF per Share
$-4.2
Short interest
6.9%
Employees
38
Rev per Employee
$0.0
Show more

Is Kala Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Kala Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Kala Pharmaceuticals, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Kala Pharmaceuticals, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Kala Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
12% 12%
-
- Research and Development Expense 22 22
4% 4%
-
-39 -39
1% 1%
-
- Depreciation and Amortization 0.26 0.26
10% 10%
-
EBIT (Operating Income) EBIT -40 -40
1% 1%
-
Net Profit -36 -36
10% 10%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kala Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kala Pharmaceuticals, Inc. Stock News

Neutral
The Motley Fool
16 days ago
Kala Bio (KALA -2.19%), a clinical-stage biopharmaceutical company focused on novel therapies for eye diseases, released its second quarter 2025 results on August 8, 2025. The headline was a net loss per share of $1.71 (GAAP).
Neutral
GlobeNewsWire
16 days ago
-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9 million as of June 30, 2025, expected to fund operations into 1Q 2026 --
Neutral
GlobeNewsWire
18 days ago
ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference being held virtually on...
More Kala Pharmaceuticals, Inc. News

Company Profile

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Watertown, MA.

Head office United States
CEO Todd Bazemore
Employees 38
Founded 2009
Website www.kalarx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today